LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$46.74 MCurrent assets$1.46 BLiabilities$1.22 BAssets$2.19 BNon-current liabilities$1.17 BNon-current assets$728.76 MEquity$967.52 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsShort-term investmentsAccounts receivable, netShort-term portion of financial royalty assets, netInventoryOther current assetsIncome taxes receivableIntangible assets, netLong-term portion of financial royalty assets, netOther investmentsGoodwillEquity method investmentsDeferred income taxes, netNoncurrent derivative assetsOther assetsAccrued liabilitiesAccounts payableIncome taxes payableCurrent operating lease liabilitiesOther current liabilitiesCurrent contingent liabilitiesConvertible senior notes, netDeferred income taxes, netOther long-term liabilitiesLong-term operating lease liabilitiesLong-term contingent liabilitiesRetained earningsAdditional paid-in capitalAccumulated other comprehensive incomeCommon stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityAccrued liabilitiesAccrued liabilities$31.87 MAccounts payableAccounts payable$9.41 MCurrent liabilitiesCurrent liabilities$46.74 MCash and cash equivalentsCash and cash equivalents$1.01 BIncome taxes payableIncome taxes payable$3.22 MCurrent assetsCurrent assets$1.46 BCurrent operating lease liabilitiesCurrent operating lease liabilities$1.08 MOther current liabilitiesOther current liabilities$955.00 KShort-term investmentsShort-term investments$351.06 MLiabilitiesLiabilities$1.22 BCurrent contingent liabilitiesCurrent contingent liabilities$210.00 KAssetsAssets$2.19 BAccounts receivable, netAccounts receivable, net$67.01 MShort-term portion of financial royalty assets, netShort-term portion of financial royalty assets, net$12.98 MNon-current liabilitiesNon-current liabilities$1.17 BInventoryInventory$10.26 MConvertible senior notes, netConvertible senior notes, net$1.13 BOther current assetsOther current assets$6.19 MIncome taxes receivableIncome taxes receivable$2.91 MDeferred income taxes, netDeferred income taxes, net$21.65 MIntangible assets, netIntangible assets, net$209.24 MOther long-term liabilitiesOther long-term liabilities$17.22 MLong-term portion of financial royalty assets, netLong-term portion of financial royalty assets, net$194.23 MLong-term operating lease liabilitiesLong-term operating lease liabilities$3.78 MNon-current assetsNon-current assets$728.76 MOther investmentsOther investments$114.48 MLong-term contingent liabilitiesLong-term contingent liabilities$2.38 MEquityEquity$967.52 MGoodwillGoodwill$101.54 MRetained earningsRetained earnings$583.25 MEquity method investmentsEquity method investments$42.39 MDeferred income taxes, netDeferred income taxes, net$37.12 MAdditional paid-in capitalAdditional paid-in capital$379.77 MNoncurrent derivative assetsNoncurrent derivative assets$17.91 MAccumulated other comprehensive incomeAccumulated other comprehensive income$4.48 MOther assetsOther assets$11.84 MCommon stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCommon stock$20.00 K
Chart details

LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
2,185,875,000 US dollars
Current assets
1,457,116,000 US dollars
Non-current assets
728,759,000 US dollars
Liabilities
1,218,359,000 US dollars
Current liabilities
46,736,000 US dollars
Non-current liabilities
1,171,623,000 US dollars
Equity
967,516,000 US dollars
Cash and cash equivalents
1,006,702,000 US dollars
Short-term investments
351,056,000 US dollars
Accounts receivable, net
67,011,000 US dollars
Short-term portion of financial royalty assets, net
12,982,000 US dollars
Inventory
10,263,000 US dollars
Other current assets
6,191,000 US dollars
Income taxes receivable
2,911,000 US dollars
Intangible assets, net
209,244,000 US dollars
Long-term portion of financial royalty assets, net
194,228,000 US dollars
Other investments
114,483,000 US dollars
Goodwill
101,541,000 US dollars
Equity method investments
42,390,000 US dollars
Deferred income taxes, net
37,119,000 US dollars
Noncurrent derivative assets
17,913,000 US dollars
Other assets
11,841,000 US dollars
Accrued liabilities
31,867,000 US dollars
Accounts payable
9,405,000 US dollars
Income taxes payable
3,217,000 US dollars
Current operating lease liabilities
1,082,000 US dollars
Other current liabilities
955,000 US dollars
Current contingent liabilities
210,000 US dollars
Convertible senior notes, net
1,126,594,000 US dollars
Deferred income taxes, net
21,654,000 US dollars
Other long-term liabilities
17,216,000 US dollars
Long-term operating lease liabilities
3,777,000 US dollars
Long-term contingent liabilities
2,382,000 US dollars
Retained earnings
583,251,000 US dollars
Additional paid-in capital
379,769,000 US dollars
Accumulated other comprehensive income
4,476,000 US dollars
Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
20,000 US dollars
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025
0 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!